Primary peritoneal carcinoma
Therapeutic area
Oncology
Rare disease
Yes
- Definition
- A rare carcinoma that arises from the peritoneum and resembles the malignant surface epithelial-stromal tumors that arise from the ovary. Serous adenocarcinoma is the most common histologic variant. It affects women almost exclusively. The diagnosis of primary peritoneal carcinoma can be made only if both ovaries are not involved by tumor, or, if the ovaries are involved, the tumor is confined to the ovarian surface without invasion of the ovarian stroma and the peritoneal involvement is greater than the ovarian surface involvement.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Primary peritoneal carcinoma
- Therapeutic area
- Oncology
- primary peritoneal carcinoma
- EOPPC
- Extra-ovarian primary peritoneal carcinoma
- PPC
- primary peritoneal cancer
- primary peritoneal carcinoma
- primary peritoneal carcinoma (disease)
- primary peritoneal serous carcinoma
- serous surface papillary carcinoma
- All therapeutic areas
- Oncology
- Severity
- Severe
- MONDO ID
- MONDO:0015686
- Parent condition
- MONDO:0002113
Related records
Broader conditions (12)
- Cancer
- Cancer or benign tumor
- Carcinoma
- Disease
- Disease by etiologic mechanism
- Epithelial neoplasm
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
- Peritoneal carcinoma
- Peritoneal neoplasm
- Peritoneum cancer
Narrower conditions (2)
- Primary peritoneal serous adenocarcinoma
- Primary peritoneal serous/papillary carcinoma
Trials (394)
- "Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- A Beta-only IL-2 ImmunoTherapY Study
- A Biomarker Screening Protocol for Participants With Solid Tumors
- A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
- A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer
- A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
- A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer
- A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
- A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
- A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
- A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
- A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
- A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
- A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
- A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
- A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α（FRα）
- A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
- A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
- A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer